Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Armodafinil adjunctive therapy in Bipolar I Depression
NCT00481195Phase 2Completed
- Sponsor
- Cephalon, Inc.
- Start
- Jun 2007
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in bipolar I disorder comparing Armodafinil with Placebo (2 arms). Primary endpoint: Mean Change From Baseline to Endpoint (Week 8 or Last Observation After Baseline) in the 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30). Started Jun 2007; status: completed.
02
Drugs
armodafinil
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT00481195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00481195.